VIVOS THERAPEUTICS INC (VVOS) Fundamental Analysis & Valuation

NASDAQ:VVOS • US92859E2072

1.39 USD
-0.05 (-3.47%)
Last: Mar 5, 2026, 11:17 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VVOS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VVOS. VVOS was compared to 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of VVOS have multiple concerns. While showing a medium growth rate, VVOS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. VVOS Profitability Analysis

1.1 Basic Checks

  • VVOS had negative earnings in the past year.
  • In the past year VVOS has reported a negative cash flow from operations.
  • VVOS had negative earnings in each of the past 5 years.
  • VVOS had a negative operating cash flow in each of the past 5 years.
VVOS Yearly Net Income VS EBIT VS OCF VS FCFVVOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • VVOS has a Return On Assets of -66.70%. This is amonst the worse of the industry: VVOS underperforms 90.10% of its industry peers.
  • The Return On Equity of VVOS (-675.51%) is worse than 81.19% of its industry peers.
Industry RankSector Rank
ROA -66.7%
ROE -675.51%
ROIC N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
VVOS Yearly ROA, ROE, ROICVVOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • Looking at the Gross Margin, with a value of 55.74%, VVOS is in the better half of the industry, outperforming 78.22% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VVOS has declined.
  • VVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
VVOS Yearly Profit, Operating, Gross MarginsVVOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. VVOS Health Analysis

2.1 Basic Checks

  • VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VVOS has more shares outstanding
  • VVOS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for VVOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VVOS Yearly Shares OutstandingVVOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
VVOS Yearly Total Debt VS Total AssetsVVOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • VVOS has an Altman-Z score of -7.62. This is a bad value and indicates that VVOS is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -7.62, VVOS is not doing good in the industry: 88.12% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 3.36 is on the high side and indicates that VVOS has dependencies on debt financing.
  • VVOS has a Debt to Equity ratio of 3.36. This is in the lower half of the industry: VVOS underperforms 76.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.36
Debt/FCF N/A
Altman-Z -7.62
ROIC/WACCN/A
WACC8.7%
VVOS Yearly LT Debt VS Equity VS FCFVVOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.78 indicates that VVOS may have some problems paying its short term obligations.
  • With a Current ratio value of 0.78, VVOS is not doing good in the industry: 84.16% of the companies in the same industry are doing better.
  • VVOS has a Quick Ratio of 0.78. This is a bad value and indicates that VVOS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • VVOS has a worse Quick ratio (0.78) than 77.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78
VVOS Yearly Current Assets VS Current LiabilitesVVOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. VVOS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 68.84% over the past year.
  • The Revenue has grown by 18.76% in the past year. This is quite good.
  • VVOS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.70% yearly.
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
Revenue 1Y (TTM)18.76%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%75.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.97% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, VVOS will show a very strong growth in Revenue. The Revenue will grow by 36.29% on average per year.
EPS Next Y28.96%
EPS Next 2Y24.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.91%
Revenue Next 2Y36.29%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VVOS Yearly Revenue VS EstimatesVVOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
VVOS Yearly EPS VS EstimatesVVOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. VVOS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VVOS. In the last year negative earnings were reported.
  • Also next year VVOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVOS Price Earnings VS Forward Price EarningsVVOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVOS Per share dataVVOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • VVOS's earnings are expected to grow with 24.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.97%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VVOS Dividend Analysis

5.1 Amount

  • No dividends for VVOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VVOS Fundamentals: All Metrics, Ratios and Statistics

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (3/5/2026, 11:17:41 AM)

1.39

-0.05 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-19
Earnings (Next)03-30
Inst Owners11.96%
Inst Owner Change-3.89%
Ins Owners16.39%
Ins Owner Change0%
Market Cap13.12M
Revenue(TTM)17.32M
Net Income(TTM)-17.10M
Analysts80
Price Target5.1 (266.91%)
Short Float %6.44%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.13%
Min EPS beat(2)-40.06%
Max EPS beat(2)5.81%
EPS beat(4)2
Avg EPS beat(4)-3.51%
Min EPS beat(4)-40.06%
Max EPS beat(4)30.5%
EPS beat(8)4
Avg EPS beat(8)-3.42%
EPS beat(12)7
Avg EPS beat(12)6.07%
EPS beat(16)8
Avg EPS beat(16)0.24%
Revenue beat(2)1
Avg Revenue beat(2)18.61%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)38.2%
Revenue beat(4)1
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-19.36%
Max Revenue beat(4)38.2%
Revenue beat(8)2
Avg Revenue beat(8)0.82%
Revenue beat(12)2
Avg Revenue beat(12)-4.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)12.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B 5.18
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS1.83
BVpS0.27
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.7%
ROE -675.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.74%
FCFM N/A
ROA(3y)-124.43%
ROA(5y)-96.22%
ROE(3y)-1313.92%
ROE(5y)-818.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7%
GM growth 5Y-4.62%
F-Score2
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 3.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.02%
Cap/Sales 5.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z -7.62
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)121.46%
Cap/Depr(5y)141.96%
Cap/Sales(3y)5.11%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
EPS Next Y28.96%
EPS Next 2Y24.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.76%
Revenue growth 3Y-3.81%
Revenue growth 5Y5.7%
Sales Q2Q%75.73%
Revenue Next Year24.91%
Revenue Next 2Y36.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.36%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.97%
OCF growth 3YN/A
OCF growth 5YN/A

VIVOS THERAPEUTICS INC / VVOS FAQ

What is the ChartMill fundamental rating of VIVOS THERAPEUTICS INC (VVOS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VVOS.


Can you provide the valuation status for VIVOS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to VIVOS THERAPEUTICS INC (VVOS). This can be considered as Overvalued.


How profitable is VIVOS THERAPEUTICS INC (VVOS) stock?

VIVOS THERAPEUTICS INC (VVOS) has a profitability rating of 1 / 10.


Can you provide the financial health for VVOS stock?

The financial health rating of VIVOS THERAPEUTICS INC (VVOS) is 0 / 10.


Can you provide the expected EPS growth for VVOS stock?

The Earnings per Share (EPS) of VIVOS THERAPEUTICS INC (VVOS) is expected to grow by 28.96% in the next year.